Beta 3 agonist treatment in heart failure (BEAT-HF II) - BEAT-HF II

Hjertemedicinsk klinik, Rigshospitalet0 sites70 target enrollmentJune 16, 2016

Overview

No summary available.

Registry

who.int

Start Date

June 16, 2016

End Date

TBD

Last Updated

4 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

Hjertemedicinsk klinik, Rigshospitalet

•1\.Stable heart failure NYHA class II\-III on ischemic or non\-ischemic basis
•2\.Left ventricular ejection fraction (LVEF) \< 35% as assessed by cardiac CT
•3\.Stable sinus rhythm (SR)
•4\.On optimised evidence\-based pharmacological HF treatment stable \> 4 weeks with no current plan for changing HF therapy. The therapy must include a beta\-blocker.
•5\.No change in diuretics \<4 weeks
•6\.\>18 years
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 40

•1\.Acute myocardial infarction (AMI) or revascularisation \< 3 month ago
•2\.Atrial fibrillation (for technical reasons in relation to imaging and HR reporting)
•3\.Uncorrected significant primary obstructive valve disease
•4\.Planned major surgery including cardiac revascularisation
•5\.Hemodynamically significant obstructive cardiomyopathy
•6\.Acute myocarditis or constrictive pericarditis
•7\.Clinically significant hepatic (transaminases or bilirubin x 3 above upper reference level) or renal (GFR\< 40 ml/min/1,73 m2\) diseases
•8\.Heart failure due to uncorrected thyroid disease
•9\.Cardiac mechanical support
•10\.\< 6 months after CRT